Trade Aligos Therapeutics, Inc. - ALGS CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.2184 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023457% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001235% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 4.6758 |
| Open | 4.4658 |
| 1-Year Change | 414.73% |
| Day's Range | 4.2758 - 4.5058 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 15, 2025 | 4.6758 | 0.1200 | 2.63% | 4.5558 | 5.6358 | 4.5558 |
| Apr 14, 2025 | 4.5758 | 0.3600 | 8.54% | 4.2158 | 4.6258 | 4.0658 |
| Apr 11, 2025 | 4.0358 | 0.1100 | 2.80% | 3.9258 | 4.2158 | 3.7158 |
| Apr 10, 2025 | 3.9558 | -0.8400 | -17.52% | 4.7958 | 4.7958 | 3.8258 |
| Apr 9, 2025 | 4.9558 | 0.5300 | 11.98% | 4.4258 | 5.0758 | 4.2158 |
| Apr 8, 2025 | 4.6258 | -0.6900 | -12.98% | 5.3158 | 5.5058 | 4.4658 |
| Apr 7, 2025 | 4.9558 | -0.5100 | -9.33% | 5.4658 | 5.6958 | 4.7658 |
| Apr 4, 2025 | 5.8858 | -0.0900 | -1.51% | 5.9758 | 5.9758 | 4.9958 |
| Apr 3, 2025 | 6.4358 | -0.4300 | -6.26% | 6.8658 | 6.8658 | 6.3658 |
| Apr 2, 2025 | 7.3358 | 0.5700 | 8.42% | 6.7658 | 7.8258 | 6.7658 |
| Apr 1, 2025 | 7.0158 | -1.0300 | -12.80% | 8.0458 | 8.2358 | 6.9858 |
| Mar 31, 2025 | 8.1358 | -0.3300 | -3.90% | 8.4658 | 8.5858 | 7.4758 |
| Mar 28, 2025 | 8.8658 | -0.6400 | -6.73% | 9.5058 | 9.6358 | 8.7958 |
| Mar 27, 2025 | 9.4958 | 0.0000 | 0.00% | 9.4958 | 9.6358 | 9.0358 |
| Mar 26, 2025 | 9.5158 | -1.4000 | -12.83% | 10.9158 | 11.1658 | 9.4658 |
| Mar 25, 2025 | 10.6258 | -0.9700 | -8.37% | 11.5958 | 11.6558 | 10.4158 |
| Mar 24, 2025 | 11.4458 | 0.1000 | 0.88% | 11.3458 | 11.4858 | 10.3958 |
| Mar 21, 2025 | 10.7158 | -0.4500 | -4.03% | 11.1658 | 11.3858 | 10.6358 |
| Mar 20, 2025 | 11.4758 | 0.0900 | 0.79% | 11.3858 | 11.9858 | 11.2858 |
| Mar 19, 2025 | 11.6258 | 0.8500 | 7.89% | 10.7758 | 11.7158 | 10.6358 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Aligos Therapeutics, Inc. Company profile
About Aligos Therapeutics Inc
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapeutics to address unmet medical needs in viral and liver diseases. It uses its oligonucleotide and small molecule platforms to develop pharmacologically optimized drug candidates for use in combination regimens. It is initially focused on developing functional cure for Chronic Hepatitis B (CHB); cirrhosis, end-stage liver disease (ESLD) and hepatocellular carcinoma (HCC). It developing a portfolio of differentiated drug candidates for CHB, including an S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPS) molecule, a small molecule Capsid Assembly Modulator (CAM), and oligonucleotides, such as ASO and Small interfering RNA (siRNA), each of which is designed against targets in the Hepatitis B Virus (HBV) life cycle. The Company's pipeline includes ALG-010133, ALG-000184, ALG-020572, ALG-125097 and ALG-055009.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Aligos Therapeutics Inc revenues increased from $0K to $4.4M. Net loss increased 18% to $128.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase of 12% to $88.3M (expense), Stock-based Compensation in R&D increase from $1M to $7.6M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
One Corporate Dr., 2Nd Floor
2nd Floor
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com